[Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer].

Molecular target therapy is one of the most popular field of non-small cell lung cancer (NSCLC) treatmnet. Epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearragement are the most important two oncogenic drivers in NSCLC, early studies suggested that EGFR mutations and ALK rearrangements are mutually exclusive, but isolated cases or small sample research with concomitant EGFR and ALK alterations have been constantly reported. The co-occurrence of EGFR mutations and anaplastic lymphoma kinase (ALK) rearrangements constitutes a rare molecular, the frequency of EGFR/ALK co-alterations was about 1%, however, little has been known about clinicopathologic feature and treatment. This review summarized published case report, EGFR and ALK alterations are common in female, Asian origin, never smoker, IV stage, and denocarcinomas. First-line treatment can choose EGFR or ALK tyrosine kinase inhibitors (TKIs). However, studies about the origin and resistance mechanism in EGFR/ALK co-alterations are little, require more experimental and clinical research. .【中文题目：非小细胞肺癌EGFR和ALK基因双突变 研究进展】 【中文摘要：分子靶向治疗是目前非小细胞肺癌（non-small cell lung cancer, NSCLC）最热门研究的领域之一，表皮生长因子受体（epidermal growth factor receptor, EGFR）和间变淋巴瘤激酶（anaplastic lymphoma kinase, ALK）是NSCLC最重要的两个驱动基因，早期研究认为是独立的分子事件，相互排斥，但不断有EGFR和ALK双突变的病例或小样本研究报道。EGFR和ALK双突变作为罕见分子事件，发生率约为1%，其临床病理特点还不很清楚，治疗缺乏定论。本综述汇总已发表病例报道，发现EGFR和ALK基因双突变多见于女性、东亚、不吸烟、IV期肺腺癌，一线治疗可选择EGFR或ALK酪氨酸激酶抑制剂（tyrosine kinase inhibitors, TKIs）。然而，目前双突变的起源和耐药机制研究较少，需要更深入的基础和临床研究。】 【中文关键词：肺肿瘤；表皮生长因子受体；间变淋巴瘤激酶】.